Browse by author
Lookup NU author(s): Dr Paul Donaghy, Dr Michael FirbankORCiD, Dr George Petrides, Nicola Barnett, Kirsty OlsenORCiD, Dr Nicola HeslehurstORCiD, Professor Alan ThomasORCiD, Professor John O'Brien
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Introduction Amyloid-β (Aβ) deposition is common in dementia with Lewy bodies (DLB) and has been associated with more rapid disease progression. An effective biomarker that identified the presence of significant brain Aβ in people with DLB may be useful to identify and stratify participants for research studies and to inform prognosis in clinical practice. Plasma biomarkers are emerging as candidates to fulfil this role. Methods Thirty-two participants with DLB had brain amyloid (18F-florbetapir) PET, of whom 27 also had an MRI to enable the calculation of 18F-florbetapir SUVR. Plasma Aβ42/40, phosphorylated tau (ptau181), glial fibrillary acidic protein (GFAP) and neurofilament light (NfL) were measured using single molecule array (Simoa). The plasma biomarkers were investigated for correlation with 18Fflorbetapir SUVR, discriminant ability to identify Aβ-positive cases based on a predefined SUVR threshold of 1.10 and correlation with subsequent cognitive decline over one year. Results All four plasma markers significantly correlated with 18F-florbetapir SUVR (|β|=.40-.49; p<.05). NfL had the greatest area under the receiver operating characteristic curve to identify Aβ-positive cases (AUROC .84 (95% CI .66, 1); β=.46, p=.001), whereas Aβ42/40 had the smallest (AUROC .73 (95% CI .52, .95); β=-.47, p=.01). Accuracy was highest when combining all four biomarkers (AUROC .92 (95% CI .80, 1)). Lower plasma Aβ42/40 was significantly associated with more rapid decline in cognition (β=.53, p<.01). Conclusions Plasma biomarkers have the potential to identify Aβ deposition in DLB. Further work in other cohorts is required to determine and validate optimal cut-offs for these biomarkers.
Author(s): Donaghy PC, Firbank M, Petrides G, Lloyd J, Barnett N, Olsen K, Heslegrave A, Zetterberg H, Thomas AJ, O'Brien JT
Publication type: Article
Publication status: Published
Journal: Parkinsonism and Related Disorders
Year: 2022
Volume: 101
Pages: 111-116
Print publication date: 01/08/2022
Online publication date: 19/07/2022
Acceptance date: 17/07/2022
Date deposited: 01/08/2022
ISSN (print): 1353-8020
ISSN (electronic): 1873-5126
Publisher: Elsevier
URL: https://doi.org/10.1016/j.parkreldis.2022.07.008
DOI: 10.1016/j.parkreldis.2022.07.008
Altmetrics provided by Altmetric
